Literature DB >> 26944732

Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.

Francesca M Notarangelo1, Ana Pocivavsek2.   

Abstract

The kynurenine pathway (KP) of tryptophan degradation contains several neuroactive metabolites that may influence brain function in health and disease. Mounting focus has been dedicated to investigating the role of these metabolites during neurodevelopment and elucidating their involvement in the pathophysiology of psychiatric disorders with a developmental component, such as schizophrenia. In this review, we describe the changes in KP metabolism in the brain from gestation until adulthood and illustrate how environmental and genetic factors affect the KP during development. With a particular focus on kynurenic acid, the antagonist of α7 nicotinic acetylcholine (α7nACh) and N-methyl-d-aspartate (NMDA) receptors, both implicated in modulating brain development, we review animal models designed to ascertain the role of perinatal KP elevation on long-lasting biochemical, neuropathological, and behavioral deficits later in life. We present new data demonstrating that combining perinatal choline-supplementation, to potentially increase activation of α7nACh receptors during development, with embryonic kynurenine manipulation is effective in attenuating cognitive impairments in adult rat offspring. With these findings in mind, we conclude the review by discussing the advancement of therapeutic interventions that would target not only symptoms, but potentially the root cause of central nervous system diseases that manifest from a perinatal KP insult. This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alpha 7 nicotinic receptor; Choline; Cognition; Kynurenic acid; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 26944732      PMCID: PMC5010529          DOI: 10.1016/j.neuropharm.2016.03.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  158 in total

Review 1.  Pharmacotherapeutic implications of the association between genomic instability at chromosome 15q13.3 and autism spectrum disorders.

Authors:  Stephen I Deutsch; Maria R Urbano; Jessica A Burket; Amy L Herndon; Erin E Winebarger
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

Review 2.  Apoptosis in the in vivo mammalian forebrain.

Authors:  K Dikranian; M J Ishimaru; T Tenkova; J Labruyere; Y Q Qin; C Ikonomidou; J W Olney
Journal:  Neurobiol Dis       Date:  2001-06       Impact factor: 5.996

3.  Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway.

Authors:  Mazura Pisar; Caroline M Forrest; Omari S Khalil; Kara McNair; Maria C J Vincenten; Susana Qasem; L Gail Darlington; Trevor W Stone
Journal:  Brain Res       Date:  2014-06-21       Impact factor: 3.252

4.  Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor.

Authors:  Roberto Pellicciari; Rosa C Rizzo; Gabriele Costantino; Maura Marinozzi; Laura Amori; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  ChemMedChem       Date:  2006-05       Impact factor: 3.466

5.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

6.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.

Authors:  Arash Rassoulpour; Hui-Qiu Wu; Sergi Ferre; Robert Schwarcz
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

7.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

8.  Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice.

Authors:  Linnéa Asp; Maria Holtze; Susan B Powell; Håkan Karlsson; Sophie Erhardt
Journal:  Int J Neuropsychopharmacol       Date:  2009-07-17       Impact factor: 5.176

9.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 10.  G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease.

Authors:  Nina Divorty; Amanda E Mackenzie; Stuart A Nicklin; Graeme Milligan
Journal:  Front Pharmacol       Date:  2015-03-10       Impact factor: 5.810

View more
  32 in total

1.  Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine.

Authors:  Ana Pocivavsek; Greg I Elmer; Robert Schwarcz
Journal:  Hippocampus       Date:  2018-12-04       Impact factor: 3.899

Review 2.  Basic Neuroscience Illuminates Causal Relationship Between Sleep and Memory: Translating to Schizophrenia.

Authors:  Ana Pocivavsek; Laura M Rowland
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

3.  Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice.

Authors:  Francesca M Notarangelo; Sarah Beggiato; Robert Schwarcz
Journal:  Dev Neurosci       Date:  2019-05-22       Impact factor: 2.984

Review 4.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

5.  Restraint Stress during Pregnancy Rapidly Raises Kynurenic Acid Levels in Mouse Placenta and Fetal Brain.

Authors:  Francesca M Notarangelo; Robert Schwarcz
Journal:  Dev Neurosci       Date:  2017-02-18       Impact factor: 2.984

6.  Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats.

Authors:  Sarah Beggiato; Alessandro Ieraci; Maria Cristina Tomasini; Robert Schwarcz; Luca Ferraro
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-02-04       Impact factor: 5.067

7.  Prefrontal α7nAChR Signaling Differentially Modulates Afferent Drive and Trace Fear Conditioning Behavior in Adolescent and Adult Rats.

Authors:  Anabel M M Miguelez Fernández; Hanna M Molla; Daniel R Thomases; Kuei Y Tseng
Journal:  J Neurosci       Date:  2021-01-21       Impact factor: 6.167

8.  Exposure to elevated embryonic kynurenine in rats: Sex-dependent learning and memory impairments in adult offspring.

Authors:  Silas A Buck; Annalisa M Baratta; Ana Pocivavsek
Journal:  Neurobiol Learn Mem       Date:  2020-07-30       Impact factor: 2.877

9.  Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.

Authors:  Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

10.  Stress-induced impairment in fear discrimination is causally related to increased kynurenic acid formation in the prefrontal cortex.

Authors:  Alex D Klausing; Tsutomu Fukuwatari; David J Bucci; Robert Schwarcz
Journal:  Psychopharmacology (Berl)       Date:  2020-03-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.